Relapsed or refractory adult acute lymphoblastic leukemia (ALL) carries a grave prognosis. The most promising strategy for curing these patients is through re-induction chemotherapy followed by successful allogeneic transplant. We studied a new high-dose induction regimen inorder to improve the outcome for these patients. Eighteen adult patients with relapsed/ refractory ALL were treated on a phase I study of high-dose cytarabine combined with a single escalating dose of idarubicin. Five patients had primary refractory disease and 13 were treated in refractory relapse. Nine patients (50%) had Ph ؉ ALL. 
Introduction
Curent chemotherapy induction regimens result in complete remission for 65-85% of adult patients with acute lymphoblastic leukemia (ALL). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] There is a significant relapse rate, however, and only 20-30% of all patients will be cured of their disease. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Therefore the majority of adults with ALL will require therapy for relapsed or refractory disease.
Traditionally, salvage regimens have relied on combinations of vincristine, prednisone and additional agents which reiterate initial induction strategies. 12, 13 More recently, therapy for relapsed and refractory patients has focused on highdose cytarabine containing regimens. High-dose cytarabine as a single agent can produce responses in approximately 30% of relapsed/refractory patients. 14 In combination with L-asparaginase, [15] [16] [17] doxorubicin, 18 idarubicin, 19, 20 or mitoxantrone, [21] [22] [23] complete responses in as many as 59% of patients have been reported. Experience at our institution and elsewhere with cytarabine and a single high dose of mitoxantrone indicates that the combination is quite active in adult ALL. 1, 24 Idarubicin is a particularly interesting drug to administer as a single large dose based on the long half-life of its active metabolite idarubicinol. We therefore conducted a phase I dose escalation study of a single dose of idarubicin combined with high-dose cytarabine to determine the MTD of idarubicin when given in this regimen.
Materials and methods

Trial design
Between January 1994 and August 1996, 18 previously treated adult patients with the diagnoses of ALL (17 patients) or lymphoblastic lymphoma (one patient) were entered on this study. Patients were between 18 and 60 years of age with a diagnosis of relapsed or refractory ALL or lymphoblastic lymphoma. The induction regimen consisted of cytarabine (Ara-C) 3.0 g/m 2 /day intravenously over 3 h on days 1-5. Idarubicin was administered as a single dose on day 3. Three patients were accrued to each dose level. If there was one occurrence of grade 4 non-hematologic toxicity at a particular dose level, three additional patients were accrued at that dose level. Two patients experiencing grade 4 non-hematologic toxicity closed accrual to that dose level and defined the preceding dose as the phase II dose. Patients were treated at idarubicin dose levels of 20 
Evaluation criteria
The diagnosis of ALL (or lymphoblastic lymphoma) was based on morphologic evaluation of the bone marrow aspirate (or lymph node biopsy). In addition, histochemical, immunophenotypic and cytogenetic analyses were performed as adjunctive studies. Chromosome preparations were obtained according to conventional methods following short-term culture. Metaphase preparations were stained to reveal Giemsa and/or quinacrine banding patterns. Patients were classified as relapsed, primary refractory, or refractory relapse, based on their response to prior therapy. Patients who relapsed while not on active therapy were classified as 'relapsed'. Patients who never achieved a CR despite at least one standard course of induction therapy were considered to be 'primary refractory'. Patients who relapsed while receiving chemotherapy or those who relapsed and did not achieve a second CR to a standard re-induction regimen were classified as in 'refractory relapse'.
A complete response was defined as the disappearance of all clinical evidence of leukemia for a minimum of 4 weeks. The patient had to have a neutrophil count greater than 1000/l, a platelet count greater than 100 000/l, no circulating blasts, and a normal bone marrow differential (less than 5% blasts) in a qualitatively normal or hypercellular bone marrow.
Patients not achieving a CR were considered failures and removed from study. The survival of patients was measured from the initiation of the protocol therapy. Duration of complete response was measured from the initial CR until documentation of relapse. Toxicity was graded according to the National Cancer Institute common toxicity criteria.
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Results
Patient characteristics
A total of 18 patients were treated on this protocol (Table 1) . There were 13 men and five women. The median age was 32 with a range of 20-56 years. Seventeen patients had ALL and one patient had lymphoblastic lymphoma without bone marrow involvement. Nine patients (50%) had Ph + ALL. There were four cohorts of patients treated (Table 2) at idarubicin dose levels of 20 mg/m 2 (three patients), 30 mg/m 2 (three patients), 40 mg/m 2 (eight patients) and at 50 mg/m 2 (four patients). At the time of enrollment on study one patient had relapsed disease, one patient had primary refractory ALL, and 16 patients were in refractory relapse.
Toxicity
Toxicities are presented in Table 3 . As expected with this high-dose regimen all patients developed grade 4 hematologic ) therapy died of congestive heart failure 66 days after receiving high-dose idarubicin. This patient had achieved a CR to this regimen prior to the cardiac death. The second patient to die at the 50 mg/m 2 dose level developed progressive pneumonia while pancytopenic and died of uncontrolled infection on day 31 of therapy. This patient died with a hypocellular bone marrow without evidence of leukemia. These two patients experiencing grade 4 non-hematologic toxicity closed accrual to this dose level and defined 40 mg/m 2 as the MTD for this trial. 
Discussion
The majority of adult patients with ALL will relapse from their initial CR or will never achieve a first CR. 26 Therefore, most adult patients with ALL will be treated in a relapsed or refractory setting at some point in their disease course. Current strategies for this frequently encountered entity are inadequate as relapsed patients are only infrequently cured. The best chance for curing these patients appears to be induction of second CR followed by an allogeneic transplant. In order to optimize the likelihood of achieving a CR prior to transplant we investigated a high-dose induction regimen which combines cytarabine with a single high dose of idarubicin.
Idarubicin is a synthetic antineoplastic anthracycline. Although the precise mechanism of action is unknown, it has an inhibitory effect on nucleic acid synthesis possibly via intercalation and unwinding of the DNA chain as well as through interactions with topoisomerase 2. The absence of a methoxy group at position 4 of the anthracycline structure gives idarubicin a high lipophilicity which results in an increased rate of cellular uptake compared to other anthracylines. Moreover, in contrast to other anthracyclines, idarubicinol, the active metabolite of idarubicin is also an active cyto- toxic anthracycline. The long half-life of idarubicinol (Ͼ41 h) makes idarubicin an attractive drug to administer as a single large dose. We postulated that a single large dose of idarubicin would achieve both high-peak plasma levels as well as prolonged cytotoxic levels of anthracycline. In this way we planned to achieve a higher fractional cell kill by eliminating cells sensitive to only high-peak levels as well as those requiring prolonged exposure to cytotoxic levels. The present study was designed to identify the MTD of idarubicin given in combination with high-dose cytarabine and to assess the toxicity of this combination when administered to adult patients with relapsed or refractory ALL. In this study we determined that an idarubicin dose of 50 mg/m 2 was found to have unacceptable toxicity in this patient population. This conclusion is based on two patient deaths in a cohort of four patients. Since one death was secondary to cardiotoxicity in a patient with significant prior anthracycline and anthracenedione exposure, it is not clear if previously untreated, anthracycline naive, patients may be able to tolerate a higher dose of idarubicin than the group studied in this report. Future approaches to ameliorate the potential cardiotoxicity of this regimen in patients with signifiant prior anthracycline exposure might include incorporating drugs such as the cardioprotectant dexrozoxane into the treatment regimen.
We conclude that concomitant administration of cytarabine 3 g/m 2 /day × 5 days and idarubicin 40 mg/m 2 as a single dose on day 3 can be administered with acceptable safety to relapsed and refractory adult patients with ALL. In this trial we note that this regimen appears active but small patient numbers limit the certainty of this observation. We have recently initiated a multi-center phase II trial to further evaluate the safety and efficacy of this high-dose regimen in a larger group of adult patients with relapsed or refractory ALL.
